Boston Scientific (BSX) reported that its SEISMIQ 4CE coronary intravascular lithotripsy catheter met all primary safety and effectiveness endpoints in the pivotal FRACTURE trial, supporting regulatory plans and drawing fresh attention to the stock.

Despite the positive FRACTURE trial news and other recent updates such as the MiRus investment and a US$2b accelerated share repurchase, momentum has been weak. The share price is down 40.2% year to date and the 1 year total shareholder return is down 45.8%, although the 5 year total shareholder return of 35.5% shows longer term holders have still seen gains overall.

If you are interested in how medical technology trends are playing out beyond Boston Scientific, it could be worth scanning 30 healthcare AI stocks

With the stock down sharply over the past year and trading below some intrinsic value estimates, the key question now is whether Boston Scientific is genuinely undervalued or if the market is already pricing in its future growth.

Most Popular Narrative: 42.7% Undervalued

According to the most followed narrative, Boston Scientific's fair value of $98.90 sits well above the last close at $56.67, which is a wide gap for a large medical device company and helps explain why some investors see the recent weakness as a potential mispricing.

The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons:

• Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which has been reflected in the recent price dips.
• Increased Debt Load: BSX is financing a significant portion of this deal (about $11 billion) with new debt. This has raised concerns about the company’s leverage, with projections reaching 3.3x adjusted EBITDA leverage by the end of 2026.
• Valuation Premium: Some market participants view the $14.5 billion price tag as high, leading to a "show me" period in which the stock price may remain under pressure until the integration is demonstrated to be successful.

The narrative from Bill_S focuses on how this acquisition could reshape growth, margins and earnings power once early dilution and higher leverage are behind the company. The key questions relate to which revenue mix assumptions and profitability targets sit underneath that almost $100 fair value, and how they connect to a premium multiple usually reserved for faster growing sectors.

Result: Fair Value of $98.90 (UNDERVALUED)

However, the bullish case could be knocked off course if Penumbra integration is slower or more costly than planned, or if higher leverage limits future flexibility.

Next Steps

If this mix of optimism and caution has you on the fence, consider acting while sentiment is still resetting and review the 5 key rewards

Looking for more investment ideas?

If Boston Scientific has sharpened your focus, now is the moment to widen your search and line up a few more stocks that could suit your goals.

• Spot potential turnaround stories by scanning 27 elite penny stocks with strong financials that pair smaller size with stronger financial profiles than many investors expect.
• Zero in on quality at a sensible price by reviewing the 51 high quality undervalued stocks that combine robust fundamentals with more modest valuations.
• Prioritise staying power by checking the 67 resilient stocks with low risk scores that score well on resilience while keeping downside risk in tighter check.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.